



* TEST * You  Invite to P virtual webinar * TEST *

Janssen Oncology <RA-JACIEDU-JanIRepMB@inform.janssen-emea.com>

Thu 2/11/2021 10:04 AM

To: Islam, Arif [JACGB Non-J&J] <Alslam5@its.jnj.com>

This is a promotional email from Janssen.

Prescribing information can be found at www.medicines.ie and adverse events reporting information can be found at the end of this email.



{{customText(255|CustomerName)}},

I hope you're keeping well.[Due to the current circumstances, while I can't see you...	▼
I hope you're keeping well.[Due to the current circumstances, while I can't see you face to face, I'm sending this information which you may find beneficial.	
How are you? I hope this email finds you well.	
I appreciated your time when we last spoke.	
Several other customers appreciated some support material on subcutaneous patients.	
I hope you are adjusting to the new normal that we all find ourselves in. It certainly is a whole new world. I'm sending you this information as discussed.	
I hope you are adjusting to the new normal that we all find ourselves in. It certainly is a whole new world. I'm sending you this information and I hope you find it beneficial.	
I know things are different in terms of working now.	
I'd just like to send you this information.	

~~I would like to invite you to join our virtual webinar with Prof. María-Victoria Mateos. Prof. María-Victoria is a consultant physician in the Hematology Department and Associate Professor of Medicine at the University of Salamanca, Spain.~~

~~The purpose of this meeting will be to discuss how triplet combination of Daratumumab, Bortezomib, and Dexamethasone improves Multiple Myeloma survival in 1PL~~

~~The date and time of this session will be:~~

~~**Friday 5th March 2021 from 09:30am to 10:30am**~~

~~Please click on the link below to add to your calendar and access meeting link.~~



If you have any further questions please do not hesitate to [contact me](#).

Kind regards,

{{userName}}

{{User.Title}}

{{userEmailAddress}}

{{User.MobilePhone}}

Adverse events should be reported. ▼ This medicinal product is subject to additional monitoring and it is therefore important to report any suspected adverse events related to this medicinal product. Healthcare

professionals are asked to report any suspected adverse events via: HPRA Pharmacovigilance, Earlsort Terrace Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, Website: www.hpra.ie, Email: medsafety@hpra.ie. Adverse events should also be reported to Janssen Sciences Ireland UC on 1800 709 122 or at dsafety@its.jnj.com.

CONFIDENTIALITY NOTICE:

The information contained in this email is intended only for the individual or entity to whom it is addressed. It may contain privileged and confidential information and if you are not an intended recipient you must not copy, distribute, or take any action in reliance on it. If you have received this email in error, notify us immediately by email at RA-JACIEDU-JanIRepMB@ITS.JNJ.com. Please destroy and delete this message from your computer.

If you wish to stop receiving emails from Janssen please reply "**stop**" to the following inbox: emailpermission@its.jnj.com.

MARKETING AUTHORISATION HOLDER: Janssen-Cilag International NV, Turnhoutseweg 30, B-2340 Beerse, Belgium

Legal Category: Prescription Only Medicine

Item Code: C-27107
Date of Preparation: February 2021

For more information
visit Janssen Medical Cloud

janssen
Medical Cloud™

FURTHER INFORMATION IS AVAILABLE FROM

Janssen Sciences Ireland UC, Barnahely, Ringaskiddy, Co.Cork, Ireland. Registered in Ireland No 472372.

© Janssen Sciences Ireland UC 2021